Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?

Key Takeaways BMY gained 6.3% in a month, outperforming the industry, sector, and broader market indexes.Newer drugs like Reblozyl, Breyanzi, and Opdualag are helping offset legacy drug patent expirations.Recent pipeline setbacks in Reblozyl, Camzyos, and Cobenfy phase III trials raise investor concerns.Bristol Myers ((BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The stock regained some of its lost ground and added 6.3% in a month compared with t ...